NO983641L - Fremgangsmåte til behandling og farmasöytisk preparat - Google Patents

Fremgangsmåte til behandling og farmasöytisk preparat

Info

Publication number
NO983641L
NO983641L NO983641A NO983641A NO983641L NO 983641 L NO983641 L NO 983641L NO 983641 A NO983641 A NO 983641A NO 983641 A NO983641 A NO 983641A NO 983641 L NO983641 L NO 983641L
Authority
NO
Norway
Prior art keywords
treatment
pharmaceutical preparation
loratadine
allergy
inflammation
Prior art date
Application number
NO983641A
Other languages
English (en)
Norwegian (no)
Other versions
NO983641D0 (no
Inventor
Sven-Erik Dahlen
Edward M Scolnick
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO983641D0 publication Critical patent/NO983641D0/no
Publication of NO983641L publication Critical patent/NO983641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO983641A 1996-02-08 1998-08-07 Fremgangsmåte til behandling og farmasöytisk preparat NO983641L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1132896P 1996-02-08 1996-02-08
GBGB9608927.1A GB9608927D0 (en) 1996-04-29 1996-04-29 Method of treatment and pharmaceutical composition
PCT/US1997/001799 WO1997028797A1 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composion

Publications (2)

Publication Number Publication Date
NO983641D0 NO983641D0 (no) 1998-08-07
NO983641L true NO983641L (no) 1998-08-07

Family

ID=26309231

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983641A NO983641L (no) 1996-02-08 1998-08-07 Fremgangsmåte til behandling og farmasöytisk preparat

Country Status (19)

Country Link
EP (1) EP1014972A4 (is)
JP (1) JPH11504044A (is)
KR (1) KR19990082367A (is)
CN (1) CN1210465A (is)
AU (1) AU732671B2 (is)
BG (1) BG102669A (is)
BR (1) BR9707369A (is)
CA (1) CA2245162A1 (is)
CZ (1) CZ248798A3 (is)
EE (1) EE9800234A (is)
IL (1) IL125446A0 (is)
IS (1) IS4805A (is)
NO (1) NO983641L (is)
NZ (1) NZ331160A (is)
PL (1) PL328074A1 (is)
SK (1) SK105698A3 (is)
TR (1) TR199801511T2 (is)
WO (1) WO1997028797A1 (is)
YU (1) YU33298A (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
DK1041990T3 (da) * 1997-12-23 2006-10-02 Schering Corp Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
PE20001070A1 (es) * 1998-09-10 2000-10-19 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
AU2002227240A1 (en) * 2000-10-30 2002-05-15 Schering Corporation Treatment and method using loratadine and montelukast
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
WO2004087095A2 (es) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositivo osmótico que contiene zafirlukast y un antagonista h1
EP1680084A2 (en) * 2003-10-21 2006-07-19 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
WO2005089748A1 (en) * 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
WO2006047427A1 (en) 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
TR200806298A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
CN102834406A (zh) 2009-06-16 2012-12-19 默沙东公司 作为糖皮质激素受体激动剂的新的[3.2-c]杂芳基甾体、其组合物和用途
KR101540191B1 (ko) * 2014-02-24 2015-07-28 성균관대학교산학협력단 로라타딘을 포함하는 항염증용 조성물
MA54707A (fr) * 2019-01-10 2021-11-17 Jiangyin Mucocare Pharmaceutical Co Ltd Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
CZ248798A3 (cs) 1999-01-13
NO983641D0 (no) 1998-08-07
AU2257997A (en) 1997-08-28
TR199801511T2 (xx) 1998-10-21
PL328074A1 (en) 1999-01-04
CA2245162A1 (en) 1997-08-14
YU33298A (en) 1999-11-22
JPH11504044A (ja) 1999-04-06
KR19990082367A (ko) 1999-11-25
AU732671B2 (en) 2001-04-26
IS4805A (is) 1998-07-22
WO1997028797A1 (en) 1997-08-14
NZ331160A (en) 2000-07-28
SK105698A3 (en) 1999-05-07
EE9800234A (et) 1998-12-15
EP1014972A1 (en) 2000-07-05
CN1210465A (zh) 1999-03-10
BR9707369A (pt) 1999-07-20
IL125446A0 (en) 1999-03-12
BG102669A (bg) 1999-04-30
EP1014972A4 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
NO983641L (no) Fremgangsmåte til behandling og farmasöytisk preparat
NO993847D0 (no) Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
NO20004282L (no) Matriksproteinpreparater for sÕrheling
ATE207342T1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
NO985464L (no) Konsentrert antistoffpreparat
EE9700060A (et) 2-arüül-asendatud püridiinid,nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
EE9800136A (et) Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine
EE9900075A (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
EE9600172A (et) Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid
ITRM920412A0 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico.
FI971188L (fi) Terapeuttinen vitamiini-kalsium yhdistelmä yksikköannoksena galeenisen tabletin muodossa, menetelmä sen valmistamiseksi ja sen käyttö
SE9603725D0 (sv) New teatment
IS1864B (is) Nýjar bensímídasólafleiður sem vinna gegn magasári, aðferðir til að útbúa þær og lyfjablöndur sem innihalda þær
NO992062D0 (no) Preparat for behandling av astma, inneholdende loratadin og et dekongestionsmiddel
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
FI951631A7 (fi) Substituoituja kynureniinejä, menetelmä niiden valmistamiseksi ja niid en käyttö lääkkeinä
ATE343391T1 (de) Behandlung von pansenacidose mit amylasehemmern
NO921906D0 (no) Nye 2-amino-5-cyano-1,4-dihydropyridiner, deres fremstilling og anvendelse i legemidler
NO985807L (no) Transdermale systemer inneholdende 2 aktive ingredienser i separate seksjoner, deres fremstillingsprosess og deres anvendelse som medikament
NO304378B1 (no) Nye imidazopyridinderivater som er angiotensin II-antagonister, farmas°ytiske preparater som inneholder dem, og deres anvendelse til fremstilling av medikamenter
NO863460D0 (no) Fremgangsmaate til fremstilling av 6-fenoksymetyl-4-hydroksy-tetrahydropyran-2-on, fremgangsmaate til deres fremstilling, og deres anvendelse som legemiddel, farmasoeytiske preparater og mellomprodukter.
NO985791D0 (no) Enhet for transdermal administrering av trimegeston, fremgangsmÕte for fremstilling av enheten og anvendelse av denne som medikament
NO20031108L (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet